Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CVP + HiCy for Adult Burkitt Lymphoma
NCT00133991Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2005
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Burkitt lymphoma (BL) and Burkitt leukemia, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Overall Response Rate at 3 months, Overall Survival at 3 years and 2 more. Started Jul 2005; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)Burkitt leukemia
Beyond the preview
Go deeper on NCT00133991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133991.